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Objectives: The aim of the present study was to evaluate whether
polymorphisms of the mannose-binding lectin (MBL-2) gene and MBL
serum levels on admission to neonatal intensive care unit are associated
with necrotizing enterocolitis (NEC) in preterm infants and to verify MBL
expression in NEC bowels.
Methods: In this retrospective cohort study, 107 neonates (41 with NEC and
66 controls) were included. MBL-2 genotyping for the promoter
polymorphism 221 and for the exon 1 variant alleles at codons 52, 54,
and 57 was performed. MBL levels were determined by enzyme-
linked immunosorbent assay in 55 infants. Immunohistochemical staining
for MBL expression was performed on bowel specimens. The main study
outcome was severe NEC (Bell stages II/III).
Results: The 221 Y allele and the MBL-2 YY genotype were more
frequent in neonates with severe NEC than in controls (P¼ 0.04 and
P¼ 0.004, respectively). In the multivariate analysis, the MBL-2YA/YA
genotype was associated with NEC (odds ratio¼ 3.03, 95% confidence
interval 1.13%–8.13%, P¼ 0.024). Neonates with NEC had MBL level on
admission >400 ng/mL more frequently than controls (P¼ 0.043). Among
neonates with severe NEC, the deceased neonates were carriers of high or
intermediate producing MBL-2 genotypes (P¼ 0.035). Finally, MBL was
highly expressed in intestinal tissue from infants with NEC.
Conclusions: MBL-2 genotypes associated with high MBL serum levels
represent a risk factor for NEC. This finding, together with the MBLKey Words: mannose-binding lectin, MBL-2 gene, necrotizing
enterocolitis, preterm infants
(JPGN 2012;55: 160–165)N ecrotizing enterocolitis (NEC) is the most commonand serious gastrointestinal disorder among preterm
infants. It is a leading cause of morbidity and mortality: approxi-
mately 12% of premature infants weighing <1500 g will become
afflicted with NEC, and about one-third of them will succumb to
the disease. Although prematurity, gut motility, intestinal impaired
blood flow, formula feeding, and bacterial colonization have
been implicated, the pathogenesis of NEC remains unclear (1).
Numerous data suggest that the unifying hypothesis between
these pathogenetic factors could be the uncontrolled exuberant
inflammatory response to bacterial colonization together with the
inadequate anti-inflammatory response observed in the immature
intestine (1).
The innate immune system represents the first line of defense
before the neonates can mount an appropriate adaptive immune
response (2). Mannose-binding lectin (MBL) is a receptor of the
innate immune system. It is particularly important because it binds
and opsonises a variety of pathogens and activates the lectin path-
way of complement, providing rapid protection against microbial
invasion (3). MBL serum levels are genetically determined (4).
Three structural single nucleotide polymorphisms (SNPs) of the
MBL-2 gene exon 1, at codons 52, 54, and 57, interfere with the
assembly of the protein, causing decreased functional MBL levels.
In addition, the 221 X/Y promoter SNP affects the protein expres-
sion, the 221Y variant being associated with higher MBL levels
(5). Human MBL is characteristically produced by hepatocytes,
but an extrahepatic transcription in the human intestine has also
been described, suggesting that MBL expression may participate in
the local immune defense in this site (6).
We hypothesized that MBL may have a role in intestinal
injury during NEC and that SNPs of the MBL-2 gene related to high
MBL expression could be a risk factor for severe NEC. Therefore,
we have investigated whether SNPs of the MBL-2 gene and
high serum MBL levels were associated with severe NEC in a
retrospective cohort of preterm infants admitted to our neonatal
intensive care unit (NICU).
To further support the relation between the induction of
the proinflammatory response and the intestinal tissue injury, we
have also examined the expression of MBL in biopsy bowelduction of this article is prohibited.
neonates who underwent surgery during
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Patients
This retrospective cohort study comprised 107 neonates, with
a gestational age (GA) of32 weeks, consecutively admitted to our
NICU between January 2005 and December 2008. Among these
neonates, 41 had NEC and 66 were not affected. Among 41
neonates with NEC, 33 (80.5%) developed the disease during
hospitalization in our unit and 8 (19.5%) were referred to our
NICU because of either suspected or overt NEC. A whole-blood
sample was collected for the 107 neonates enrolled, together with
informed consent from parents, for genetic analysis. From 55 of 107
neonates, a serum sample was collected on admission to the NICU
(median day of life 1; interquartile range [IQR] 1–8) for measure-
ment of MBL levels. Serum samples were not obtained from
neonates with symptoms of infection or suspected or overt NEC.
Patients’ characteristics and clinical data were searched
retrospectively, using the neonatal database of the unit and the
patients’ charts. The following demographic and clinical charac-
teristics on admission to the NICU were recorded: sex, birth weight
(BW), GA, prenatal steroids exposure, mode of delivery, Apgar
score at 50, need for intubation and ventilation at birth, mode
of delivery, presence of respiratory distress syndrome, patent
ductus arteriosus beyond the third day of life, and development
of infections during hospitalization.
NEC was defined according to the Bell classification system
(7). For the analysis, ‘‘severe NEC’’ definition included Bell stages
II and III, and ‘‘NEC’’ included Bell stages I, II, and III.
MBL-2 Genotyping
Genomic DNA was extracted from ethylenediaminetetra-
acetic acid blood samples using QIAmp DNA Blood kit (Qiagen,
Hilden, Germany). Typing of the MBL gene exon 1 (mutant codons
52, 54, and 57) and promoter (position 221) was performed
by polymerase chain reaction and restriction fragment length
polymorphism. For exon 1, the wild-type allele was designated
as A, whereas B, C, and D were, respectively, mutants in codon 54,
57, and 52. For the promoter, the wild-type allele was designated as
Y (position 221), whereas X was the mutant. The 3 MBL-2
structural gene mutations B, C, and D (collectively referred as
O) are in linkage disequilibrium with the promoter region poly-
morphism X/Y, so that only Y associates with variant alleles (5).
According to Garred et al (8), we grouped MBL-2 genotypes in
high (YA/YA), intermediate (YA/XA, XA/XA), and low/deficient
(YA/YO, YO/XA, YO/YO) MBL-expressing groups.
Measurement of MBL
Serum MBL was measured using an immunoassay (MBL
oligomer ELISA, Antibody Shop, Copenhagen, Denmark) accord-
ing to the instruction provided by the manufacturer. The linear range
was 0.25 to 40 ng/mL. Sera were diluted 1:300 in the sample diluent
provided by the manufacturer. The lowest detectable MBL con-
centration was 0.075 ng/mL. Results below the limit of detection
were allocated a value of 0.05 ng/mL for statistical purposes.
MBL Immunohistochemistry
Intestinal specimens were obtained from infants with
NEC stage III who underwent surgical bowel resection (n¼ 9).
Both necrotic and perilesional areas were examined. Moreover,
JPGN  Volume 55, Number 2, August 2012pyright 2012 by ESPGHAN and NASPGHAN. Un
healthy intestinal specimens were obtained from patients who
previously had NEC and underwent ileostomy (n¼ 12), as well
www.jpgn.orgas from age-matched patients (n¼ 3), who underwent ileostomy
because of Meckel diverticulum. Intestinal tissue was fixed in
neutral buffered formalin and embedded in paraffin. After moist
heat-induced antigen retrieval with 1 mmol/L ethylenediaminete-
traacetic acid at pH 9.0, 3-mm sections were incubated with a
mouse monoclonal antibody to human MBL (Santa Cruz Biotech,
Santa Cruz, CA) for 1 hour at room temperature or with an irrelevant
mouse immunoglobulin G1. After washing, the presence of MBL
was revealed with the labeled Streptavidin-Biotin2 System (Dako
Cytomation, Carpinteria, CA), based on the use of a biotinylated
secondary antibody and peroxidase conjugated streptavidin. The
procedure was in accordance with the instructions of the manu-
facturer. 3-30 Diaminobenzidine was used as a chromogen and
counterstaining was done with hematoxylin (Dako Cytomation).
Statistical Analysis
For the statistical analyses, we used the Statistical Package
for Social Sciences (SPSS Inc, Chicago, IL) and STATA (StataCorp,
College Station, TX). Quantitative data were expressed as
medians and IQRs, and frequencies were compared by the x2 test
or the Fisher exact test. For the genotype frequency analysis of
the promoter 221 XY, we classified patients into 2 groups:
those carrying at least 1 MBL-221 X allele (XY and XX) and
those carrying the YY genotype because only 1 patient was a carrier
of the XX genotype.
We performed uni- and multivariate logistic regression
analyses: the main outcome was the occurrence of NEC (severe
NEC and NEC). All of the variables associated with the risk of
NEC in univariate analyses with P< 0.05 were included in the
multivariate analysis. P< 0.05 was considered significant.
RESULTS
Patients’ Characteristics
Among 107 preterm neonates included in the study, 41 were
affected by NEC (stage I, n¼ 20; stage II, n¼ 3; and stage III,
n¼ 18) and 66 were not affected (controls). Neonates with NEC
were analyzed as 2 groups: severe NEC (stages II and III) and NEC
(stages I, II, and III) and compared with controls. Table 1 shows the
clinical characteristics of the patients: low GA, low BW, confirmed
infections, and death were more frequent in severe NEC neonates
compared with controls.
Analysis of MBL-2 Genotype and Association
With NEC
We have genotyped 4 common SNPs of the MBL-2 gene:
codons 52, 54, and 57 in the exon 1 and 221 in the promoter
region. Allele and genotype frequencies for all of the studied SNPs
are summarized in Table 2. The frequency of the promoter 221Y
allele was higher in patients with severe NEC than in controls
(P¼ 0.04). Moreover, neonates with severe NEC showed an
increased probability of carrying the YY genotype compared with
controls (odds ratio [OR] 5.1, 95% confidence interval [CI] 1.55%–
16.8%; P¼ 0.004). Conversely, the allelic frequencies of the exon 1
polymorphisms C and B were similar in neonates with severe
NEC and in control neonates; we did not found neonates with
the D variant allele. Naming ‘‘O’’ the MBL-2 structural variant
alleles B and C, the frequency of AA, AO, and OO genotypes
between neonates with severe NEC and controls was similar.
At the genotypic analysis, the frequency of the high-
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MBL-level related YA/YA genotype was increased in neonates
with severe NEC compared with controls (OR 3.03, 95% CI
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TABLE 1. Clinical characteristics and procedures in neonates with severe NEC (stages II–III), NEC (stages I, II, and III), and in
neonates without NEC (controls)
Clinical characteristic
and procedures
Controls,
n¼ 66
Severe NEC,
n¼ 21 P
NEC,
n¼ 41 P
White ethnicity, % 93.9 90.5 NSy 92.7 NS
Male sex, % 50.0 42.9 NS 51.2 NS
Gestational age, wkz 28 (26–30) 26 (25–29) 0.02 27 (26–29) 0.07
Birth weight, gz 1165 (830–1360) 880 (638.75–1063.75) 0.04 910 (737.5–1107.5) 0.01
Small for gestational age, % 7.6 19.0 NS 17.1 NS
Prenatal steroids, % 69.7 52.6 NS 58.5 NS
Cesarean section, % 75.7 61.9 NS 68.3 NS
Apgar 50 5, % 18.2 14.3 NS 14.6 NS
Orotracheal intubation, % 18.2 28.6 NS 24.4 NS
Respiratory distress syndrome, % 90.9 100 NS 95.1 NS
Surfactant administration, % 75.7 84.2 NS 73.2 NS
Patent ductus arteriosus, % 50.0 66.7 NS 68.3 NS
Infection§, % 53.0 80.0 0.02 58.5 NS
Death, % 7.6 52.4 <0.001 29.3 0.003
NEC¼ necrotizing enterocolitis. x2 test. yNot significant. zContinuous variables are reported as median and IQR. §Confirmed infections diagnosed
before the development of NEC in cases and during the whole hospitalization in controls.
Prencipe et al JPGN  Volume 55, Number 2, August 20121.13%–8.13%, P¼ 0.024) (Table 3). When we looked at all of the
neonates with NEC (stages I, II, and III), the allele and genotypepyright 2012 by ESPGHAN and NASPGHAN. Un
frequencies of the considered SNPs were similar to those observed
in neonates with severe NEC. At univariate analysis, GA and
TABLE 2. Distribution of allele and genotype frequencies of 4 SN
and III), NEC neonates (stages I, II, and III), and controls
Controls,
n¼ 66
Severe NEC,
n¼ 21
Alleles
Promoter alleles
221 G!C (allele X)
G 96 (72.7) 38 (90.5) 2.78
C 36 (27.3) 4 (9.5)
Structural exon 1 alleles
Codon 54 G!A (allele B)
G 110 (83.3) 37 (88.1)
A 22 (16.7) 5 (11.9)
Codon 57 G!A (allele C)
G 130 (98.5) 41 (97.6)
A 2 (1.5) 1 (2.3)
Genotypes
Promoter 221 genotypes
YY 30 (45.5) 17 (81.0) 5.1
XYþXX 36 (54.5) 4 (19.0)
Structural exon 1 genotypes
AA 45 (68.2) 17 (81.0)
AO 18 (27.3) 2 (9.5)
OO 3 (4.5) 2 (9.5)
Data are expressed as number and (%). CI¼ confidence interval; MBL¼m
SNP¼ single nucleotide polymorphism.
162infections were significantly associated with severe NEC. At multi-
variate analysis, with GA, BW, and infections as covariates, theauthorized reproduction of this article is prohibited.
YA/YA genotype remained independently associated with severe
NEC (OR 4.42, 95% CI 1.11%–17.49%, P¼ 0.03) or with NEC
Ps in the MBL-2 gene among severe NEC neonates (stages II
OR (95% CI);
P
NEC,
n¼ 41
OR (95% CI);
P
(1.01%–7.6%); 0.04 71 (86.6) 2.42 (1.15%–5.08%); 0.017
11 (13.4)
NS 73 (89.0) NS
9 (11.0)
NS 80 (97.6) NS
2 (2.4)
(1.55–16.8); 0.004 31 (75.6) 3.72 (1.57–8.81); 0.002
10 (24.4)
NS 32 (78) NS
7 (17.1)
2 (4.9)
annose-binding lectin; NEC¼ necrotizing enterocolitis; OR¼ odd ratio;
www.jpgn.org
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TABLE 3. Genotypes of MBL-2 exon 1 and S221 promoter region in infants with NEC and controls
MBL-2 genotype
Controls,
n¼ 66
Severe NEC,
n¼ 21
OR (95% CI);
P
NEC
n¼ 41
OR (95% CI);
P
High MBL group
YA/YA 19 (28.8) 13 (61.9) 3.03 (1.13%–8.13%); 0.024 24 (58.5) 3.49 (1.54%–7.92%); 0.002
Intermediate MBL group
YA/XAþXA/XA 26 (39.4) 4 (19.0) NS 8 (19.5) NS
Low MBL group
YA/YBþYC 9 (13.6) 2 (9.5) NS 6 (14.6) NS
XA/YBþYC 9 (13.6) 0 1 (2.4)
YO/YO 3 (4.5) 2 (9.5) 2 (4.9)
CI¼ confidence interval; MBL¼mannose-binding lectin; NEC¼ necrotizing enterocolitis; OR¼ odds ratio.
JPGN  Volume 55, Number 2, August 2012 Necrotizing Enterocolitis and Genetics(stages I–II and III) (OR 3.48, 95% CI 1.22%–9.94%; P¼ 0.02).
Similar results were obtained eliminating from the cohort all
nonwhite neonates (data not shown), excluding the possibility that
the inclusion of these neonates could lead to a bias.
We did not observe a significant difference in the
frequency of the YA/YA carriers between deceased and survived
infants (data not shown); however, all 11 deceased neonates with
severe NEC carried a high or intermediate MBL-2 genotype.
Conversely, 4 of the 10 survivors were low/deficient genotype
carriers (YA/YO or XA/YO or YO/YO; P¼ 0.035, by Fisher
exact test).
Serum MBL Levels on Admission and
Association With NEC
A serum sample collected on admission to the NICU, in
the absence of symptoms of infection, was available from 55 of
107 neonates enrolled in the study. Twenty of these 55 neonates
subsequently developed NEC (stage I, n¼ 12; stage 2, n¼ 1; stage
III, n¼ 7) during hospitalization. Neonates with and without NEC
were similar in baseline characteristics, with exception of BW,
which was lower, but not significantly, in neonates with NEC
than in the others (median BW 905 g, IQR 805–1105 vs 1176 g,
IQR 841.25–1537.5; P¼ 0.08).
MBL levels on admission to the NICU were determined in
sera from all 55 neonates. MBL values were stratified by structural
exon 1 genotypes (AA, AO, and OO). As expected, we observed
high, medium, and low values, respectively (P< 0.01). Subdividing
these genotypes by the 221 SNP, we observed a trend toward
higher serum MBL levels in the YY carriers compared with XY
carriers (median value 1.13mg/mL, IQR 0.28–2.33 vs median value
0.85mg/mL, IQR 0.17–1.80; P¼ 0.2).
Based on previous investigations in preterm neonates (9,10),
we set the cutoff value to 400 ng/mL to discriminate MBL
deficiency. We observed that 8 of 8 (100%) neonates with severe
NEC (stages II and III) had MBL level>400 ng/mL on admission to
the NICU. Among neonates who did not develop NEC during
hospitalization, 19 of 35 (54.3%) had MBL levels >400 ng/mL
on admission to the NICU (Fisher exact test, P¼ 0.043). This
difference was also evident in all of the neonates with NEC:
18 of 20 (90%) neonates with NEC at stages I, II, and III had
MBL serum levels >400 ng/mL (OR 7.58, 95% CI 1.52%–37.3%;
P¼ 0.007). Finally, in a multivariate model of analysis, MBL levelspyright 2012 by ESPGHAN and NASPGHAN. Un
>400 ng/mL remained associated with NEC (OR 8.3, 95% CI
1.6%–42.6%; P¼ 0.01) after adjusting for GA.
www.jpgn.orgMBL Expression in the Intestine of Infants With
NEC
To confirm the functional association of MBL with
development of NEC, we investigated whether MBL was expressed
in the intestinal tissue of preterm infants. Immunohistochemical
staining with an anti-MBL antibody was performed on intestinal
biopsy specimens obtained from infants with NEC during bowel
surgical resection. The analysis revealed that MBL is highly
expressed in intestinal tissue from infants with NEC. In particular,
MBL is expressed in diseased mucosa, in endothelial cells, and in
histiocytes of the small intestine (Fig. 1A–C) and of the proximal
colon (data not shown). MBL expression was also evident in
enterocytes of perilesional uninvolved bowel segments of the same
patients (data not shown). Moreover, MBL expression was
observed in enterocytes of healthy bowel biopsy sections obtained
during surgery for ileostomy from patients, not deficient in MBL
expression, who previously had NEC (Fig. 1D–F) or who under-
went ileostomy because of Meckel diverticulum (data not shown).
As negative control for the immunohistochemical analysis, we
performed MBL staining on intestinal tissue obtained during
surgical ileostomy from a NEC preterm patient who, being OO
homozygous, was MBL deficient (Fig. 1G–I).
DISCUSSION
Evidence indicates that an abnormal response by the
premature infant to the microbial flora that colonizes the gastro-
intestinal tract may be involved in the pathogenesis of NEC. Indeed,
a stronger interleukin-8-driven proinflammatory response is
provoked in immature intestinal cells when exposed to commensal
organisms (11). Several proinflammatory cytokines, including
interleukin-6 and tumor necrosis factor-a, have also been found
in intestinal samples of infants with NEC (12). Recent studies
demonstrate that Toll-like receptors (TLRs) could be central
players in the pathways that signal in response to enteric bacteria,
favoring the development of NEC (13,14). Moreover, microarray
analysis shows that in the immature intestine, the expression of
genes involved in upregulation of inflammation is increased,
whereas the expression of negative regulators of inflammation is
decreased (15). It is therefore reasonable to hypothesize that the
onset of an uncontrolled inflammatory response by the neonatal
intestine to exposure to luminal bacteria may trigger the onset
of NEC.
As TLRs, MBL is a pattern recognition receptor (PRR) andauthorized reproduction of this article is prohibited.
plays an important role in innate immune system, coordinating,
amplifying, and synchronizing innate immune defense mechanisms
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FIGURE 1. Histologic and immunohistochemical analyses of mannose-binding lectin (MBL) expression in diseased and normal
bowel areas from preterm infants who underwent surgery for NEC. Tissue sections from the ileum were analyzed for
morphological integrity by H&E staining (C, F, I) and by immunohistochemistry to detect expression of MBL (A, B, D, E, G,
H). (A, B) Representative diseased ileum sections from a preterm neonate with NEC who underwent surgical resection. Strong
staining for MBL was detected in enterocytes, endothelial cells, and histiocytes. (D, E) Representative control ileum sections from a
preterm neonate who underwent ileostomy. Positive staining for MBL was found in enterocytes. (G–H) Representative diseased
ileum sections from a preterm neonate with necrotizing enterocolitis (NEC) who was deficient in the production of functional MBL
(OO homozygous carrier for the exon 1 MBL-2 genotype) and who underwent ileostomy. Negative staining for MBL was
E,
Prencipe et al JPGN  Volume 55, Number 2, August 2012(3). Indeed, MBL, together with the MBL-associated serine
proteases, initiate the lectin pathway of the complement system.
Moreover, it has been established that MBL has a central role in
regulating PRR signaling and inflammatory cytokine production,
acting as a TLR-2/6 co-receptor (16,17).
In the present study, we found that the 221 promoter MBL-
2 variant allele Y, being associated with higher serum MBL levels,
is significantly more common in neonates with NEC than in control
neonates. Moreover, we observed a significant association of the
221 YY promoter genotype and of the combined exon 1/promoter
221 YA/YA genotype, both causing high MBL protein levels,
with a higher risk of developing NEC, independently from GA.
Interestingly, we observed that MBL-2 genotypes related to low
MBL levels were associated with a decreased mortality among
neonates with severe NEC, suggesting that MBL levels may affect
the outcome of NEC and further supporting the hypothesis of a
role of high MBL levels in contributing to intestinal damage.
We also found that neonates with NEC had MBL serum levels
>400 ng/mL on admission to the NICU more frequently than
controls without NEC. Our observations on serum MBL levels
complement the findings of a recent study (18): high MBL-
associated serine protease-2 cord blood levels have been found
to be associated with an increased risk of NEC in preterm neonates.
It should be noted that, in the same study, the authors did not find
an association between MBL cord blood levels and NEC. This may
be because they measured MBL cord blood levels and not serum
observed. Original magnification 20 for A, D, G, 40 for B,pyright 2012 by ESPGHAN and NASPGHAN. Un
MBL levels. Cord blood MBL levels may not reflect MBL levels in
the first days of life (19).
164MBL is expressed by hepatocytes, but recent evidence
in mice indicates an extrahepatic expression in small intestine, in
which MBL-C is expressed by villous epithelial cells (20).
In humans, Seyfarth et al (6) observed low extrahepatic levels of
MBL-2 mRNA, predominantly in small intestine. We detected the
expression of MBL protein in the diseased guts of preterm infants
with NEC: MBL was strongly expressed in enterocytes, in endo-
thelial cells, and in histiocytes of the small intestine and colon.
Moreover, we observed a positive staining for MBL also in enter-
ocytes of intestinal tissues from healthy infants. It should be noted
that we did not detect any staining in the intestinal tissue from an
MBL-deficient infant. Our results are in apparent contrast to the
negligible MBL expression reported in the intestinal mucosa of
both adult healthy controls and patients with Crohn disease (21).
The discrepancy between these data and our results in neonates may
be related to the age of the patients. Indeed, the gastrointestinal tract
of the premature infant differs largely from that of an adult. It has a
fragile surface area covered by a thin monolayer of epithelial
cells that overlies a highly immunoreactive mucosa, and there is
accumulating evidence that in the newborn, especially in the
premature neonate, the defense mechanism that normally maintains
a healthy balance in intestine may be inadequate, or at least
functioning at different levels compared with what occurs in
adults (1). This is also supported by the previously mentioned
gene expression profile data (15). Therefore, these data sustain
the hypothesis that in neonates, MBL could be an important factor
H, and 10 for C, F, I.authorized reproduction of this article is prohibited.
in intestinal immunity, contributing to local innate defense and that
the local production of MBL may be biologically relevant.
www.jpgn.org
CoOur results suggest that genetically determined high MBL
production is an independent risk factor for the development of
NEC, further supporting the hypothesis that PRRs of innate immu-
nity and their mediators could be important players in the initiation
of an exaggerated inflammatory response, ultimately leading to
intestinal injury. Moreover, these results support the emerging
hypothesis of a dual role for MBL: Low MBL levels would not
be disadvantageous, but, in some circumstances, also confer a
benefit (22). Although an increased susceptibility to infections
has been reported in MBL-deficient patients, including premature
infants (23,24), other studies support a role for MBL in ischemia-
reperfusion injury (25,26), with high MBL levels associated with
more severe disease. Interestingly, ischemia and reperfusion injury
has emerged as a possible cause of NEC (27).
The relatively small sample size is the main limitation of the
present study. Future studies on larger groups of preterm infants
may be needed to clarify the role of the lectin pathway during
the neonatal age in determining the high susceptibility of this
population to NEC. Moreover, we did not genotypize the 4 P/Q
and 550 H/L MBL-2 SNPs; however, the polymorphism at
position 221 in the promoter region of the gene induces the
strongest upregulating (Y variant) effect, and it is marginally
influenced by the 4 and 550 SNPs (4).
In conclusion, this is the first study to our knowledge that
explores the potential association among MBL-2 genotype, MBL
serum levels, and development of NEC in preterm neonates.
We report that MBL genotypes, which are associated with high
serum MBL levels, were significantly more common in neonates
with NEC than in controls; neonates with NEC had MBL serum
levels>400 ng/mL on admission to the NICU more frequently than
controls without NEC; neonates with severe NEC carrying low-
expressing MBL-2 genotypes had a smaller probability of death; and
MBL is highly expressed in healthy intestinal tissue and in intestinal
biopsy specimens from infants with NEC. Our findings add to the
knowledge that genetic factors, leading to an overexpression of
MBL, may be involved in the pathway causing NEC and may
influence its outcome in preterm neonates; however, it is likely that
other polymorphisms exist at multiple points in genes regulating the
inflammatory cascade, which may account for individual suscepti-
bility in the development of NEC. Genetic analysis of the MBL-2
gene polymorphisms may help to identify subsets of premature
infants at risk of developing NEC and subsets of infants with NEC
at risk of severe outcome. Finally, because recombinant human
MBL is being developed as a therapeutic approach (28), studies
aimed at investigating the role of MBL in the neonatal period may
be useful to understand whether its administration may be beneficial
(possibly lowering risk of infections) or rather dangerous in this
delicate age group.
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